Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The patient experience.

Nadia Harbeck1, Renate Haidinger

  • 1Frauenklinik der Technischen Universität München, Ismaninger Strasse 22, Münich 81675, Germany. nadia.harbeck@lrz.tum.de

Breast Cancer Research and Treatment
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer.

Geburtshilfe und Frauenheilkunde·2024
Same author

Discussion of ABC7 Consensus and German Recommendations.

Geburtshilfe und Frauenheilkunde·2024
Same author

[Advances in breast cancer care].

MMW Fortschritte der Medizin·2024
Same author

Evaluation of the Impact of Adaptive Progressive Supervised Resistance Training on Strength and Quality of Life in Patients with Breast Cancer during Chemotherapy: The VALESCO Study.

Oncology research and treatment·2024
Same author

App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trial.

Frontiers in oncology·2024
Same author

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.

Therapeutic advances in medical oncology·2024
Same journal

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment·2026
Same journal

Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

Breast cancer research and treatment·2026
Same journal

Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.

Breast cancer research and treatment·2026
Same journal

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same journal

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Breast cancer research and treatment·2026
Same journal

Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.

Breast cancer research and treatment·2026
See all related articles

Letrozole improves outcomes for hormone-sensitive breast cancer patients by reducing progression and relapse risks. This treatment enhances long-term survival and quality of life, with manageable side effects.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Hormone-sensitive breast cancer management has evolved with increased patient awareness.
  • Patients are increasingly involved in treatment decisions, seeking information on efficacy and safety.

Purpose of the Study:

  • To evaluate the impact of letrozole on hormone-sensitive breast cancer management.
  • To assess letrozole's efficacy, safety, and quality of life implications across the breast cancer continuum.

Main Methods:

  • Literature review on letrozole's use in breast cancer.
  • Analysis of clinical outcomes, including progression, relapse, and survival.
  • Assessment of patient-reported quality of life and adverse events.

Main Results:

  • Letrozole improves outcomes in both adjuvant and metastatic hormone-sensitive breast cancer settings.

Related Experiment Videos

  • Treatment with letrozole reduces the risk of relapse and delays disease progression.
  • Quality of life is maintained, though side effects like hot flashes and arthralgia require management.

    • Conclusions:

    • Letrozole offers significant benefits for hormone-sensitive breast cancer patients, improving long-term survivorship and delaying chemotherapy needs.
    • Effective management of adverse events is crucial for patient compliance and treatment success.